English
简体中文
Total: £ 56.28
Published Date: 2025-10-08 | Pages: 111 | Tables: 105 | Medical Care
The global RDC (Radionuclide Drug Conjugate) Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
RDC (Radionuclide Drug Conjugate) services refer to professional services provided for the development, production and application of radionuclide drug conjugates. These conjugates usually combine radioisotopes with drugs (such as monoclonal antibodies, peptides or small molecules) to target specific cells or tissues for treatment, especially in cancer treatment. The main contents of RDC services include drug development, radionuclide labeling and screening, preclinical research (evaluation of drug conjugates), etc.
From a downstream perspective, Pharmaceutical Companies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
RDC (Radionuclide Drug Conjugate) Services leading manufacturers including Rdcthera, Abzena, WuXi XDC, CD Formulation, CPC Scientific Inc, etc., dominate supply; the top five capture approximately % of global revenue, with Rdcthera leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global RDC (Radionuclide Drug Conjugate) Services market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Rdcthera
Abzena
WuXi XDC
CD Formulation
CPC Scientific Inc
Segment by Type
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)
Segment by Application
Pharmaceutical Companies
Medical Device Companies
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the RDC (Radionuclide Drug Conjugate) Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to RDC (Radionuclide Drug Conjugate) Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global RDC (Radionuclide Drug Conjugate) Services Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Antibody Radionuclide Conjugates (ARC)
1.2.3 Peptide Radionuclide Conjugates (PRC)
1.2.4 Small Molecular Radionuclide Conjugates (SMRC)
1.3 Market Segmentation by Application
1.3.1 Global RDC (Radionuclide Drug Conjugate) Services Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Companies
1.3.3 Medical Device Companies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global RDC (Radionuclide Drug Conjugate) Services Revenue Estimates and Forecasts 2020-2031
2.2 Global RDC (Radionuclide Drug Conjugate) Services Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global RDC (Radionuclide Drug Conjugate) Services Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global RDC (Radionuclide Drug Conjugate) Services Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Antibody Radionuclide Conjugates (ARC) Market Size by Players
3.3.2 Peptide Radionuclide Conjugates (PRC) Market Size by Players
3.3.3 Small Molecular Radionuclide Conjugates (SMRC) Market Size by Players
3.4 Global RDC (Radionuclide Drug Conjugate) Services Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global RDC (Radionuclide Drug Conjugate) Services Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global RDC (Radionuclide Drug Conjugate) Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America RDC (Radionuclide Drug Conjugate) Services Market Size by Type (2020-2031)
6.4 North America RDC (Radionuclide Drug Conjugate) Services Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America RDC (Radionuclide Drug Conjugate) Services Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe RDC (Radionuclide Drug Conjugate) Services Market Size by Type (2020-2031)
7.4 Europe RDC (Radionuclide Drug Conjugate) Services Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe RDC (Radionuclide Drug Conjugate) Services Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Market Size by Type (2020-2031)
8.4 Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America RDC (Radionuclide Drug Conjugate) Services Market Size by Type (2020-2031)
9.4 Central and South America RDC (Radionuclide Drug Conjugate) Services Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America RDC (Radionuclide Drug Conjugate) Services Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa RDC (Radionuclide Drug Conjugate) Services Market Size by Type (2020-2031)
10.4 Middle East and Africa RDC (Radionuclide Drug Conjugate) Services Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa RDC (Radionuclide Drug Conjugate) Services Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Rdcthera
11.1.1 Rdcthera Corporation Information
11.1.2 Rdcthera Business Overview
11.1.3 Rdcthera RDC (Radionuclide Drug Conjugate) Services Product Features and Attributes
11.1.4 Rdcthera RDC (Radionuclide Drug Conjugate) Services Revenue and Gross Margin (2020-2025)
11.1.5 Rdcthera RDC (Radionuclide Drug Conjugate) Services Revenue by Product in 2024
11.1.6 Rdcthera RDC (Radionuclide Drug Conjugate) Services Revenue by Application in 2024
11.1.7 Rdcthera RDC (Radionuclide Drug Conjugate) Services Revenue by Geographic Area in 2024
11.1.8 Rdcthera RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
11.1.9 Rdcthera Recent Developments
11.2 Abzena
11.2.1 Abzena Corporation Information
11.2.2 Abzena Business Overview
11.2.3 Abzena RDC (Radionuclide Drug Conjugate) Services Product Features and Attributes
11.2.4 Abzena RDC (Radionuclide Drug Conjugate) Services Revenue and Gross Margin (2020-2025)
11.2.5 Abzena RDC (Radionuclide Drug Conjugate) Services Revenue by Product in 2024
11.2.6 Abzena RDC (Radionuclide Drug Conjugate) Services Revenue by Application in 2024
11.2.7 Abzena RDC (Radionuclide Drug Conjugate) Services Revenue by Geographic Area in 2024
11.2.8 Abzena RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
11.2.9 Abzena Recent Developments
11.3 WuXi XDC
11.3.1 WuXi XDC Corporation Information
11.3.2 WuXi XDC Business Overview
11.3.3 WuXi XDC RDC (Radionuclide Drug Conjugate) Services Product Features and Attributes
11.3.4 WuXi XDC RDC (Radionuclide Drug Conjugate) Services Revenue and Gross Margin (2020-2025)
11.3.5 WuXi XDC RDC (Radionuclide Drug Conjugate) Services Revenue by Product in 2024
11.3.6 WuXi XDC RDC (Radionuclide Drug Conjugate) Services Revenue by Application in 2024
11.3.7 WuXi XDC RDC (Radionuclide Drug Conjugate) Services Revenue by Geographic Area in 2024
11.3.8 WuXi XDC RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
11.3.9 WuXi XDC Recent Developments
11.4 CD Formulation
11.4.1 CD Formulation Corporation Information
11.4.2 CD Formulation Business Overview
11.4.3 CD Formulation RDC (Radionuclide Drug Conjugate) Services Product Features and Attributes
11.4.4 CD Formulation RDC (Radionuclide Drug Conjugate) Services Revenue and Gross Margin (2020-2025)
11.4.5 CD Formulation RDC (Radionuclide Drug Conjugate) Services Revenue by Product in 2024
11.4.6 CD Formulation RDC (Radionuclide Drug Conjugate) Services Revenue by Application in 2024
11.4.7 CD Formulation RDC (Radionuclide Drug Conjugate) Services Revenue by Geographic Area in 2024
11.4.8 CD Formulation RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
11.4.9 CD Formulation Recent Developments
11.5 CPC Scientific Inc
11.5.1 CPC Scientific Inc Corporation Information
11.5.2 CPC Scientific Inc Business Overview
11.5.3 CPC Scientific Inc RDC (Radionuclide Drug Conjugate) Services Product Features and Attributes
11.5.4 CPC Scientific Inc RDC (Radionuclide Drug Conjugate) Services Revenue and Gross Margin (2020-2025)
11.5.5 CPC Scientific Inc RDC (Radionuclide Drug Conjugate) Services Revenue by Product in 2024
11.5.6 CPC Scientific Inc RDC (Radionuclide Drug Conjugate) Services Revenue by Application in 2024
11.5.7 CPC Scientific Inc RDC (Radionuclide Drug Conjugate) Services Revenue by Geographic Area in 2024
11.5.8 CPC Scientific Inc RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
11.5.9 CPC Scientific Inc Recent Developments
12 RDC (Radionuclide Drug Conjugate) ServicesIndustry Chain Analysis
12.1 RDC (Radionuclide Drug Conjugate) Services Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 RDC (Radionuclide Drug Conjugate) Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global RDC (Radionuclide Drug Conjugate) Services Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global RDC (Radionuclide Drug Conjugate) Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global RDC (Radionuclide Drug Conjugate) Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global RDC (Radionuclide Drug Conjugate) Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global RDC (Radionuclide Drug Conjugate) Services Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global RDC (Radionuclide Drug Conjugate) Services Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global RDC (Radionuclide Drug Conjugate) Services Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global RDC (Radionuclide Drug Conjugate) Services Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global RDC (Radionuclide Drug Conjugate) Services by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RDC (Radionuclide Drug Conjugate) Services as of 2024)
Table 11. Global RDC (Radionuclide Drug Conjugate) Services Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global RDC (Radionuclide Drug Conjugate) Services Companies Headquarters
Table 13. Global RDC (Radionuclide Drug Conjugate) Services Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global RDC (Radionuclide Drug Conjugate) Services Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global RDC (Radionuclide Drug Conjugate) Services Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global RDC (Radionuclide Drug Conjugate) Services Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global RDC (Radionuclide Drug Conjugate) Services Revenue by Application (2026-2031) & (US$ Million)
Table 21. RDC (Radionuclide Drug Conjugate) Services High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America RDC (Radionuclide Drug Conjugate) Services Growth Accelerators and Market Barriers
Table 25. North America RDC (Radionuclide Drug Conjugate) Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe RDC (Radionuclide Drug Conjugate) Services Growth Accelerators and Market Barriers
Table 27. Europe RDC (Radionuclide Drug Conjugate) Services Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Growth Accelerators and Market Barriers
Table 29. Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America RDC (Radionuclide Drug Conjugate) Services Investment Opportunities and Key Challenges
Table 31. Central and South America RDC (Radionuclide Drug Conjugate) Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa RDC (Radionuclide Drug Conjugate) Services Investment Opportunities and Key Challenges
Table 33. Middle East and Africa RDC (Radionuclide Drug Conjugate) Services Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Rdcthera Corporation Information
Table 35. Rdcthera Description and Major Businesses
Table 36. Rdcthera Product Features and Attributes
Table 37. Rdcthera Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Rdcthera Revenue Proportion by Product in 2024
Table 39. Rdcthera Revenue Proportion by Application in 2024
Table 40. Rdcthera Revenue Proportion by Geographic Area in 2024
Table 41. Rdcthera RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
Table 42. Rdcthera Recent Developments
Table 43. Abzena Corporation Information
Table 44. Abzena Description and Major Businesses
Table 45. Abzena Product Features and Attributes
Table 46. Abzena Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Abzena Revenue Proportion by Product in 2024
Table 48. Abzena Revenue Proportion by Application in 2024
Table 49. Abzena Revenue Proportion by Geographic Area in 2024
Table 50. Abzena RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
Table 51. Abzena Recent Developments
Table 52. WuXi XDC Corporation Information
Table 53. WuXi XDC Description and Major Businesses
Table 54. WuXi XDC Product Features and Attributes
Table 55. WuXi XDC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. WuXi XDC Revenue Proportion by Product in 2024
Table 57. WuXi XDC Revenue Proportion by Application in 2024
Table 58. WuXi XDC Revenue Proportion by Geographic Area in 2024
Table 59. WuXi XDC RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
Table 60. WuXi XDC Recent Developments
Table 61. CD Formulation Corporation Information
Table 62. CD Formulation Description and Major Businesses
Table 63. CD Formulation Product Features and Attributes
Table 64. CD Formulation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. CD Formulation Revenue Proportion by Product in 2024
Table 66. CD Formulation Revenue Proportion by Application in 2024
Table 67. CD Formulation Revenue Proportion by Geographic Area in 2024
Table 68. CD Formulation RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
Table 69. CD Formulation Recent Developments
Table 70. CPC Scientific Inc Corporation Information
Table 71. CPC Scientific Inc Description and Major Businesses
Table 72. CPC Scientific Inc Product Features and Attributes
Table 73. CPC Scientific Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. CPC Scientific Inc Revenue Proportion by Product in 2024
Table 75. CPC Scientific Inc Revenue Proportion by Application in 2024
Table 76. CPC Scientific Inc Revenue Proportion by Geographic Area in 2024
Table 77. CPC Scientific Inc RDC (Radionuclide Drug Conjugate) Services SWOT Analysis
Table 78. CPC Scientific Inc Recent Developments
Table 79. Raw Materials Key Suppliers
Table 80. Distributors List
Table 81. Market Trends and Market Evolution
Table 82. Market Drivers and Opportunities
Table 83. Market Challenges, Risks, and Restraints
Table 84. Research Programs/Design for This Report
Table 85. Key Data Information from Secondary Sources
Table 86. Key Data Information from Primary Sources
List of Figures
Figure 1. RDC (Radionuclide Drug Conjugate) Services Product Picture
Figure 2. Global RDC (Radionuclide Drug Conjugate) Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Antibody Radionuclide Conjugates (ARC) Product Picture
Figure 4. Peptide Radionuclide Conjugates (PRC) Product Picture
Figure 5. Small Molecular Radionuclide Conjugates (SMRC) Product Picture
Figure 6. Global RDC (Radionuclide Drug Conjugate) Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Pharmaceutical Companies
Figure 8. Medical Device Companies
Figure 9. Other
Figure 10. RDC (Radionuclide Drug Conjugate) Services Report Years Considered
Figure 11. Global RDC (Radionuclide Drug Conjugate) Services Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 13. Global RDC (Radionuclide Drug Conjugate) Services Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global RDC (Radionuclide Drug Conjugate) Services Revenue Market Share by Region (2020-2031)
Figure 15. Global RDC (Radionuclide Drug Conjugate) Services Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Antibody Radionuclide Conjugates (ARC) Revenue Market Share by Player in 2024
Figure 18. Peptide Radionuclide Conjugates (PRC) Revenue Market Share by Player in 2024
Figure 19. Small Molecular Radionuclide Conjugates (SMRC) Revenue Market Share by Player in 2024
Figure 20. Global RDC (Radionuclide Drug Conjugate) Services Revenue Market Share by Type (2020-2031)
Figure 21. Global RDC (Radionuclide Drug Conjugate) Services Revenue Market Share by Application (2020-2031)
Figure 22. North America RDC (Radionuclide Drug Conjugate) Services Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) in 2024
Figure 24. North America RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Application (2020-2031)
Figure 26. US RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 27. Canada RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 29. Europe RDC (Radionuclide Drug Conjugate) Services Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) in 2024
Figure 31. Europe RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 34. France RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 36. Italy RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 37. Russia RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 43. Japan RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 45. Australia RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 46. India RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America RDC (Radionuclide Drug Conjugate) Services Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) in 2024
Figure 54. Central and South America RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa RDC (Radionuclide Drug Conjugate) Services Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) in 2024
Figure 60. South America RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa RDC (Radionuclide Drug Conjugate) Services Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2025) & (US$ Million)
Figure 63. Israel RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa RDC (Radionuclide Drug Conjugate) Services Revenue (2020-2025) & (US$ Million)
Figure 66. RDC (Radionuclide Drug Conjugate) Services Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
